Zhou Yanqing, Xiong Lipeng, Zhang Yang, Yu Rong, Jiang Xiaogang, Xu Guoqiang
Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases & College of Pharmaceutical Sciences, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, Jiangsu 215123, China.
Department of Oncology, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu 215002, China.
J Proteomics. 2016 Oct 4;148:94-104. doi: 10.1016/j.jprot.2016.07.015. Epub 2016 Jul 16.
A Disintegrin and Metalloproteinase 12 (ADAM12) is expressed significantly higher in multiple tumors than in normal tissues and has been used as a prognostic marker for the evaluation of cancer progression. Although several ADAM12 substrates have been identified biochemically and its proteolytic function has been explored, the upstream regulators and the interacting proteins have not been systematically investigated. Here, we use immunoprecipitation and mass spectrometry (MS)-based quantitative proteomic approaches to identify 28 interacting partners for the long form of ADAM12 (ADAM12-L) in HeLa cells. Proteins that regulate cell proliferation, invasion, and epithelial to mesenchymal transition are among the identified ADAM12-interacting proteins. Further biochemical experiments discover that the protein level and the stability of ADAM12 are upregulated by one of its interacting proteins, myoferlin. In addition, myoferlin also increases the proteolytic activity of ADAM12, leading to the reduction of an ADAM12 substrate, E-cadherin. This result implies that ADAM12 and its interacting proteins might converge to certain signaling pathways in the regulation of cancer cell progression. The information obtained here might be useful in the development of new strategies for modulating cell proliferation and invasion involved in the regulation between ADAM12 and its interacting partners. MS data are available via ProteomeXchange with identifier PXD003560.
Regulation of the proliferation and invasion of cancer cells is important in cancer treatment. ADAM12 has been found to play important roles in regulating these processes and identification of its interacting partners will improve our understanding of its biological functions and provide basis for functional modulation. Through mass spectrometry-based quantitative proteomic approaches, we identify the interacting partners for ADAM12 in a human cancer cell line and find many proteins that are involved in the proliferation and invasion of cancer cells. A novel regulator, myoferlin, of ADAM12 is discovered and this protein increases ADAM12 expression level, stability, and its enzymatic activity, leading to the reduction of its substrate, E-cadherin, which plays important roles in the regulation of cell adhesion and tumor metastasis. This result provides a connection for two highly expressed proteins in cancer cells and may shed light on the regulation of their biological functions in cancer progression.
解整合素金属蛋白酶12(ADAM12)在多种肿瘤中的表达显著高于正常组织,并已被用作评估癌症进展的预后标志物。尽管已经通过生物化学方法鉴定了几种ADAM12底物并探索了其蛋白水解功能,但尚未对其上游调节因子和相互作用蛋白进行系统研究。在此,我们使用基于免疫沉淀和质谱(MS)的定量蛋白质组学方法,在HeLa细胞中鉴定了28种与ADAM12长形式(ADAM12-L)相互作用的蛋白。所鉴定的与ADAM12相互作用的蛋白中包括调节细胞增殖、侵袭以及上皮-间质转化的蛋白。进一步的生化实验发现,ADAM12的一种相互作用蛋白——肌铁蛋白上调了ADAM12的蛋白水平和稳定性。此外,肌铁蛋白还增加了ADAM12的蛋白水解活性,导致一种ADAM12底物E-钙黏蛋白减少。这一结果表明,ADAM12及其相互作用蛋白可能在癌细胞进展的调节中汇聚到某些信号通路。此处获得的信息可能有助于开发新策略来调节参与ADAM12与其相互作用蛋白之间调节的细胞增殖和侵袭。MS数据可通过ProteomeXchange获得,标识符为PXD003560。
癌细胞增殖和侵袭的调节在癌症治疗中很重要。已发现ADAM12在调节这些过程中发挥重要作用,鉴定其相互作用蛋白将增进我们对其生物学功能的理解,并为功能调节提供基础。通过基于质谱的定量蛋白质组学方法,我们在人癌细胞系中鉴定了ADAM12的相互作用蛋白,并发现许多参与癌细胞增殖和侵袭的蛋白。发现了一种新的ADAM12调节因子——肌铁蛋白,该蛋白增加了ADAM12的表达水平、稳定性及其酶活性,导致其底物E-钙黏蛋白减少,E-钙黏蛋白在细胞黏附和肿瘤转移的调节中起重要作用。这一结果为癌细胞中两种高表达蛋白建立了联系,并可能揭示它们在癌症进展中生物学功能的调节机制。